© 2024 © 2020 Genprex Inc. All Rights Reserved.
Ryan Confer Appointed Genprex President and CEO and to its Board of Directors
AUSTIN, Texas — (May. 1, 2024) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company’s participation in the following upcoming investor and industry conferences to be held in May 2024.
Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments
Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices
NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex’s Acclaim-2 and Acclaim-3 clinical trials
Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer
Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association for Cancer Research (AACR) Annual Meeting